Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
ISLA-101 (fenretinide)'s own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for ISLA-101 (fenretinide). Showing past 6 months and next 12 months · 1 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| ISLA-101 (fenretinide) | Island Pharmaceuticals | Small Molecule Other | Phase 2 | 0 | ||||
| Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases | University of Sao Paulo General Hospital | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Butantan-DV Vaccine in Elderly Populations (DEN-04-IB) | Butantan Institute | — | Phase 3 | — | — | — | — | — |
| Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years. | Butantan Institute | — | Phase 3 | — | — | — | — | — |
| A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults | Takeda | — | Phase 3 | — | — | — | — | — |
| A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years) | Takeda | — | Phase 3 | — | — | — | — | — |
| A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers | Takeda | — | Phase 3 | — | — | — | — | — |
| Therapeutics for Moderate and Severe Dengue | Oxford University Clinical Research Unit, Vietnam | — | Phase 3 | — | — | — | — | — |
| A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1) | Merck Sharp & Dohme LLC | — | Phase 3 | — | — | — | — | — |
| Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients | Phramongkutklao College of Medicine and Hospital | — | PHASE2/PHASE3 | — | — | — | — | — |
| A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2) | Hyundai Bioscience Co., Ltd. | — | PHASE2/PHASE3 | — | — | — | — | — |
| Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative) | Johns Hopkins University | — | PHASE2/PHASE3 | — | — | — | — | — |
| Dengue Controlled Human Infection Model in Dhaka, Bangladesh | Beth Kirkpatrick | — | Phase 2 | — | — | — | — | — |
| Anakinra in Dengue With Hyperinflammation ( AnaDen ) | Oxford University Clinical Research Unit, Vietnam | — | Phase 2 | — | — | — | — | — |
| To Assess the Efficacy of Carica Papaya Leaf Extract in Improving Platelet Counts Among Pediatric Patients With Dengue-associated Thrombocytopenia | Ziauddin Hospital | — | Phase 2 | — | — | — | — | — |
| Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE) | George Washington University | — | Phase 2 | — | — | — | — | — |
| A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever | Novartis Pharmaceuticals | — | Phase 2 | — | — | — | — | — |
| Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2) | Federal University of Minas Gerais | — | Phase 2 | — | — | — | — | — |
| Adaptive Dengue Antiviral Platform Trial | Oxford University Clinical Research Unit, Vietnam | — | Phase 2 | — | — | — | — | — |